RxDoctor Payments Data

Shauna Basener, DO

Internal Medicine · Ames, IANPI 1902060759

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 3 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Abbott accounts for 76.3% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for internal medicine clinicians in IA, where the typical reported total is $105.

$46in general payments, 2019–2025

Across 3 payments — averaging $15.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$35
  • Novo Nordisk$11
$127,237in research payments, 2019–2025

Across 18 payments — averaging $7068.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$127K

What the payments were for

  • Food & beverage$46100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott2$35
Novo Nordisk1$11

How this compares

$46 in reported general payments places this provider in the 35th percentile of 583 internal medicine providers in Iowa.

See all internal medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$216,390
Medicare patients
361
Services billed
5,057

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban85$78,688
OzempicSemaglutide53$65,870
JardianceEmpagliflozin36$36,704
MounjaroTirzepatide23$31,707
FarxigaDapagliflozin Propanediol25$26,389
XareltoRivaroxaban20$25,155
Potassium Chloride100$10,475
Soliqua 100-33Insulin Glargine/Lixisenatide27$6,686
Fluticasone Propionate HfaFluticasone Propionate20$5,964
Estradiol74$5,722
SymbicortBudesonide/Formoterol Fumarate25$5,362
Tresiba Flextouch U-100Insulin Degludec11$4,694
Ibandronate Sodium133$4,224
Atorvastatin Calcium437$3,613
ViibrydVilazodone Hcl11$3,512

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$11$65,87053 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 583 internal medicine providers in Iowa.

Other internal medicine in Ames

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →